Synaptogenix Inc Cash Flow Conversion Efficiency
Synaptogenix Inc cash flow conversion efficiency. Based on the latest financial reports, Synaptogenix Inc (SNPX) has a cash flow conversion efficiency ratio of -0.042x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-749.07K) by net assets ($17.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Synaptogenix Inc (2018–2024)
Cash flow conversion efficiency of Synaptogenix Inc from 2018 to 2024. This chart illustrates how Synaptogenix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Synaptogenix Inc share price for real-time trading data and today's change.
Synaptogenix Inc Cash Flow Conversion Ratio Explained
Synaptogenix Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Synaptogenix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Synaptogenix Inc ranked by their cash flow conversion efficiency. Also see Synaptogenix Inc (SNPX) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
B.A.G Films and Media Limited
NSE:BAGFILMS
|
-0.017x |
|
Landmark Property Development Company Limited
NSE:LPDC
|
0.060x |
|
EA Holdings Bhd
KLSE:0154
|
-0.050x |
|
N1 Holdings Ltd
AU:N1H
|
-4.151x |
|
Tedea Technological Development and Automation Ltd
TA:TEDE
|
3.252x |
|
AB Effectenbeteiligungen AG
STU:JPH
|
N/A |
|
NETUM GROUP OYJ
F:79J
|
N/A |
|
Bitros Holding S.A
AT:MPITR
|
0.006x |
Annual Cash Flow Conversion Efficiency for Synaptogenix Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Synaptogenix Inc from 2018 to 2024. Review how financially flexible is Synaptogenix Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $6.78 Million | $-4.88 Million | -0.721x | -256.43% |
| 2023-12-31 | $25.58 Million | $-5.17 Million | -0.202x | +36.13% |
| 2022-12-31 | $35.41 Million | $-11.21 Million | -0.317x | -21.86% |
| 2021-12-31 | $33.53 Million | $-8.71 Million | -0.260x | +83.52% |
| 2020-12-31 | $5.14 Million | $-8.10 Million | -1.577x | -131.06% |
| 2019-12-31 | $17.42 Million | $-11.89 Million | -0.682x | -135.14% |
| 2018-12-31 | $26.52 Million | $-7.70 Million | -0.290x | -- |
About Synaptogenix Inc
TAO Synergies Inc. operates as a biopharmaceutical company. The company is primarily focused on developing a product platform based upon Bryostatin-1, for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X synd… Read more